ARS Pharmaceuticals, Inc. (SPRY)
(Real Time Quote from BATS)
$17.85 USD
+0.05 (0.28%)
Updated Aug 6, 2025 12:56 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SPRY 17.85 +0.05(0.28%)
Will SPRY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRY
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for
ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?
Other News for SPRY
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial ...
ARS Pharmaceuticals Inc (SPRY) Announces Upcoming Conference Call for Q2 2025 Financial Results ...
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
SPRY Gains Approval for Allergic Reaction Treatment in the UK | SPRY Stock News